Lymphatica Medtech

Executive Summary

Lymphatica Medtech is a Swiss medical device company developing a proprietary, minimally invasive platform to treat lymphatic system disorders, primarily lymphedema. The company addresses a significant unmet clinical need, as current treatments are often palliative and invasive. Founded in 2016 and based in Lausanne, Lymphatica leverages its technology to restore lymphatic function with a focus on safety and efficacy. The company is targeting initial clinical validation and regulatory clearance in Europe, with potential to transform the standard of care for millions of patients suffering from secondary lymphedema post-cancer treatment. While still private and pre-revenue, Lymphatica's innovative approach and strong IP position position it well for future growth, pending successful clinical and regulatory milestones.

Upcoming Catalysts (preview)

• Q2 2026First-in-human clinical trial results65% success
• Q4 2026CE Mark approval for lead device55% success
• Q3 2026Series B financing round70% success